Sibold William John sold $1.4M of MDGL
Sibold William John (President and CEO) sold 2,500 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $547.30 ($542.75–$555.05, $1.37M total) across 10 trades on 2026-07-20.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s open-market sale totaling $1,368,253.46 across 10 trades on 2026-07-20, with holdings after the sale of 209,329 shares and no pre-arranged 10b5-1 plan stated.
Market read
Traders may monitor for sentiment impact, but the filing alone does not provide new clinical, regulatory, or financial information.
What to watch
The article provides sale price range and share count but no context on tax, option exercises, or prior planned schedules, which can materially change interpretation.
Background
The article is a SEC Form 4 insider transaction disclosure for Madrigal Pharmaceuticals, Inc. (MDGL).
Ticker impact
Madrigal Pharmaceuticals CEO William John Sibold sold about $1.37M of MDGL shares in an open-market Form 4 transaction on 2026-07-20.
Likely limited near-term impact; any effect is more sentiment-driven than fundamental.
The filing is a routine insider sale (open-market, no 10b5-1 plan stated) with no accompanying company-specific operational or financial update in the text.
Market effects
Minimal, as this is company-specific insider activity with no sector-wide regulatory or clinical signal provided.
None indicated.
None indicated.
Counterpoint
CEO sales can be planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative outlook.
Key entities
- issuerMadrigal Pharmaceuticals, Inc.
Company whose CEO insider sale is disclosed via SEC Form 4.
- insiderSibold William John
President and CEO reporting an open-market sale of MDGL shares.